ERBB2 and breast carcinoma: In 2017, a clinical trial to investigate the optimal dosage and side effects of the 4-1BB agonist, utomilumab with trastuzumab emtansine or trastuzumab in patients with metastatic HER2-positive breast cancer was initiated (ClinicalTrials.gov Identifier: NCT03364348).